Diagnosis (Laboratory other parameters)
| Zeile 1: | Zeile 1: | ||
| + | '''any''' | ||
| + | {{tp|p=32475810|t=2020. The role of biomarkers in diagnosis of COVID-19 - A systematic review.|pdf=|usr=007}} | ||
| + | |||
'''Glucose''' | '''Glucose''' | ||
{{tp|p=32360710|t=2020. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes |pdf=|usr=}} | {{tp|p=32360710|t=2020. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes |pdf=|usr=}} | ||
| Zeile 7: | Zeile 10: | ||
'''Procalcitonin''' | '''Procalcitonin''' | ||
{{tp|p=32344321|t=2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32344321|t=2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32414743|t=2020. Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19.|pdf=|usr=007}} | ||
| + | |||
'''SAA serum amyloid a''' | '''SAA serum amyloid a''' | ||
| Zeile 14: | Zeile 19: | ||
'''suPAR''' | '''suPAR''' | ||
{{tp|p=32354367|t=2020. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia |pdf=|usr=}} | {{tp|p=32354367|t=2020. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia |pdf=|usr=}} | ||
| + | '''fever''' | ||
| + | {{tp|p=32503659|t=2020. Body temperature correlates with mortality in COVID-19 patients.|pdf=|usr=007}} | ||
| + | |||
| + | '''ESR BKS BSG''' | ||
| + | {{tp|p=32386190|t=2020. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis.|pdf=|usr=007}} | ||
'''CRP''' | '''CRP''' | ||
| Zeile 20: | Zeile 30: | ||
{{tp|p=32281668|t=2020. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early |pdf=|usr=}} | {{tp|p=32281668|t=2020. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early |pdf=|usr=}} | ||
{{tp|p=32455147|t=ä. C reactive protein level may predict the risk of COVID-19 aggravation |pdf=|usr=}} | {{tp|p=32455147|t=ä. C reactive protein level may predict the risk of COVID-19 aggravation |pdf=|usr=}} | ||
| + | {{tp|p=32511972|t=2020. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection.|pdf=|usr=007}} | ||
| + | {{tp|p=32445579|t=2020. Prognostic value of C-reactive protein in patients with COVID-19.|pdf=|usr=007}} | ||
| Zeile 27: | Zeile 39: | ||
{{tp|p=32414693|t=2020. Interleukin-6 levels in children developing SARS-CoV-2 infection |pdf=|usr=}} | {{tp|p=32414693|t=2020. Interleukin-6 levels in children developing SARS-CoV-2 infection |pdf=|usr=}} | ||
{{tp|p=32297995|t=2020. High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients |pdf=|usr=}} | {{tp|p=32297995|t=2020. High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients |pdf=|usr=}} | ||
| + | {{tp|p=32475230|t=2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.|pdf=|usr=007}} | ||
| + | {{tp|p=32428990|t=2020. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | '''IL-10''' | ||
| + | {{tp|p=32475230|t=2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.|pdf=|usr=007}} | ||
| + | {{tp|p=32501293|t=2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.|pdf=|usr=007}} | ||
| + | |||
| + | '''IL-1ra''' | ||
| + | {{tp|p=32501293|t=2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.|pdf=|usr=007}} | ||
| + | |||
| + | '''Rantes''' | ||
| + | {{tp|p=32501293|t=2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.|pdf=|usr=007}} | ||
'''NLratio''' | '''NLratio''' | ||
{{tp|p=32283162|t=ä. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 |pdf=|usr=}} | {{tp|p=32283162|t=ä. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 |pdf=|usr=}} | ||
{{tp|p=32242828|t=2020. Decreased "WBC*LYM" was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan |pdf=|usr=}} | {{tp|p=32242828|t=2020. Decreased "WBC*LYM" was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan |pdf=|usr=}} | ||
| + | {{tp|p=32458459|t=2020. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study.|pdf=|usr=007}} | ||
| + | |||
'''Troponin''' | '''Troponin''' | ||
| Zeile 46: | Zeile 73: | ||
{{tp|p=32347972|t=2020. Elevations of serum cancer biomarkers correlate with severity of COVID-19 |pdf=|usr=}} | {{tp|p=32347972|t=2020. Elevations of serum cancer biomarkers correlate with severity of COVID-19 |pdf=|usr=}} | ||
| + | '''mda5 il-24''' | ||
| + | {{tp|p=32485313|t=2020. MDA5 should be detected in severe COVID-19 patients.|pdf=|usr=007}} | ||
| + | |||
| + | '''H2S''' | ||
| + | {{tp|p=32433216|t=2020. Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Corona virus.|pdf=|usr=007}} | ||
| + | |||
| + | '''trmpss2''' | ||
| + | {{tp|p=32437018|t=2020. TMPRSS2: Potential Biomarker for COVID-19 Outcomes.|pdf=|usr=007}} | ||
| + | |||
| + | '''KL-6''' | ||
| + | {{tp|p=32470148|t=2020. Serum KL-6 concentrations as a novel biomarker of severe COVID-19.|pdf=|usr=007}} | ||
| + | |||
| + | '''monocyte distribution width''' | ||
| + | {{tp|p=32504637|t=2020. Elevated monocyte distribution width in COVID-19 patients: The contribution of the novel sepsis indicator.|pdf=|usr=007}} | ||
| + | |||
| + | '''Calcium''' | ||
| + | {{tp|p=32459190|t=2020. Low levels of total and ionized calcium in blood of COVID-19 patients.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | |||
| + | '''Urine''' | ||
| + | {{tp|p=32484450|t=2020. Urinalysis parameters for predicting severity in coronavirus disease 2019 (COVID-19).|pdf=|usr=007}} | ||
| + | |||
| + | ''ER stress''' | ||
| + | {{tp|p=32503824|t=2020. Endoplasmic Reticulum Stress Markers in SARS-COV-2 Infection and Pneumonia: Case-Control Study.|pdf=|usr=007}} | ||
| Zeile 58: | Zeile 110: | ||
{{tp|p=C7107806|t=ä. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury |pdf=|usr=}} | {{tp|p=C7107806|t=ä. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury |pdf=|usr=}} | ||
{{tp|p=32452410|t=2020. Association of viral load with serum biomakers among COVID-19 cases |pdf=|usr=}} | {{tp|p=32452410|t=2020. Association of viral load with serum biomakers among COVID-19 cases |pdf=|usr=}} | ||
| + | {{tp|p=32503382|t=2020. Biomarkers associated with COVID-19 disease progression.|pdf=|usr=007}} | ||
| + | {{tp|p=32511971|t=2020. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32508038|t=2020. Can routine laboratory tests discriminate SARS-CoV-2-infected pneumonia from other causes of community-acquired pneumonia?|pdf=|usr=007}} | ||
| + | {{tp|p=32484453|t=2020. Infection with SARS-CoV-2 causes abnormal laboratory results of multiple organs in patients.|pdf=|usr=007}} | ||
| + | {{tp|p=32441666|t=2020. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | ===host genetics=== | ||
| + | {{tp|p=32393819|t=2020. COVID-19 outcomes and the human genome.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | '''blood groups''' | ||
| + | {{tp|p=32496734|t=2020. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome.|pdf=|usr=007}} | ||
| + | {{tp|p=32453863|t=2020. COVID-19 and ABO blood group: another viewpoint.|pdf=|usr=007}} | ||
| + | |||
| + | {{tp|p=32343152|t=2020. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases |pdf=|usr=}} | ||
| + | |||
| + | '''HLA''' | ||
| + | {{tp|p=32303592|t=2020. Human leukocyte antigen susceptibility map for SARS-CoV-2 |pdf=|usr=}} | ||
| + | {{tp|p=32424945|t=2020. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19).|pdf=|usr=007}} | ||
| + | {{tp|p=32475052|t=2020. Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | '''apoE''' | ||
| + | {{tp|p=32451547|t=2020. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort.|pdf=|usr=007}} | ||
| + | |||
| + | '''on ace2, trmpss2''' | ||
| + | {{tp|p=32430459|t=2020. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits.|pdf=|usr=007}} | ||
| + | {{tp|p=32492195|t=2020. Functional prediction and frequency of coding variants in human ACE2 at binding sites with SARS-CoV-2 spike protein on different populations.|pdf=|usr=007}} | ||
| + | {{tp|p=32501810|t=2020. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | '''ace1''' | ||
| + | {{tp|p=32460534|t=2020. C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.|pdf=|usr=007}} | ||
| + | |||
| + | '''complement''' | ||
| + | {{tp|p=32460534|t=2020. C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.|pdf=|usr=007}} | ||
| + | |||
| + | '''cytokines''' | ||
| + | {{tp|p=32490733|t=2020. Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans.|pdf=|usr=007}} | ||
Version vom 23. Juni 2020, 11:42 Uhr
any
32475810 2020. The role of biomarkers in diagnosis of COVID-19 - A systematic review.
Glucose
32360710 2020. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes
Presepsin
32333860 2020. Presepsin in risk stratification of SARS-CoV-2 patients
Procalcitonin
32344321 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19
32414743 2020. Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19.
SAA serum amyloid a
32277967 ä. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19)
suPAR
32354367 2020. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
fever
32503659 2020. Body temperature correlates with mortality in COVID-19 patients.
ESR BKS BSG
32386190 2020. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis.
CRP
32368728 ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study
32344321 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19
32281668 2020. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early
32455147 ä. C reactive protein level may predict the risk of COVID-19 aggravation
32511972 2020. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection.
32445579 2020. Prognostic value of C-reactive protein in patients with COVID-19.
IL-6
32344321 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19
32259560 ä. Interleukin-6 as a potential biomarker of COVID-19 progression
32414693 2020. Interleukin-6 levels in children developing SARS-CoV-2 infection
32297995 2020. High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients
32475230 2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
32428990 2020. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.
IL-10
32475230 2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
32501293 2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.
IL-1ra
32501293 2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.
Rantes
32501293 2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.
NLratio
32283162 ä. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19
32242828 2020. Decreased "WBC*LYM" was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan
32458459 2020. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study.
Troponin
32348472 ä. A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels be Monitored in COVID-19 Patients?
Eosinophils
| 32315429 ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |
32315421 ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19)
IL2R on lymphcytes'
32365221 2020. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19
tumor markers
32347972 2020. Elevations of serum cancer biomarkers correlate with severity of COVID-19
mda5 il-24
32485313 2020. MDA5 should be detected in severe COVID-19 patients.
H2S
32433216 2020. Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Corona virus.
trmpss2
32437018 2020. TMPRSS2: Potential Biomarker for COVID-19 Outcomes.
KL-6
32470148 2020. Serum KL-6 concentrations as a novel biomarker of severe COVID-19.
monocyte distribution width
32504637 2020. Elevated monocyte distribution width in COVID-19 patients: The contribution of the novel sepsis indicator.
Calcium
32459190 2020. Low levels of total and ionized calcium in blood of COVID-19 patients.
Urine
32484450 2020. Urinalysis parameters for predicting severity in coronavirus disease 2019 (COVID-19).
ER stress'
32503824 2020. Endoplasmic Reticulum Stress Markers in SARS-COV-2 Infection and Pneumonia: Case-Control Study.
profiling multiple parameters, reviews
32283164 ä. Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China
32324595 2020. The laboratory tests and host immunity of COVID-19 patients with different severity of illness
32301746 2020. Routine blood tests as a potential diagnostic tool for COVID-19
32119647 2020. Laboratory abnormalities in patients with COVID-2019 infection
32172227 2020. Laboratory abnormalities in children with novel coronavirus disease 2019
| 32286245 2020. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis |
32181911 ä. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID?19
C7107806 ä. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury
32452410 2020. Association of viral load with serum biomakers among COVID-19 cases
32503382 2020. Biomarkers associated with COVID-19 disease progression.
32511971 2020. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19.
32508038 2020. Can routine laboratory tests discriminate SARS-CoV-2-infected pneumonia from other causes of community-acquired pneumonia?
32484453 2020. Infection with SARS-CoV-2 causes abnormal laboratory results of multiple organs in patients.
32441666 2020. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019.
host genetics
32393819 2020. COVID-19 outcomes and the human genome.
blood groups
32496734 2020. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome.
32453863 2020. COVID-19 and ABO blood group: another viewpoint.
32343152 2020. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases
HLA
32303592 2020. Human leukocyte antigen susceptibility map for SARS-CoV-2
32424945 2020. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19).
32475052 2020. Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide.
apoE
32451547 2020. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort.
on ace2, trmpss2
32430459 2020. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits.
32492195 2020. Functional prediction and frequency of coding variants in human ACE2 at binding sites with SARS-CoV-2 spike protein on different populations.
32501810 2020. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy.
ace1
32460534 2020. C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.
complement
32460534 2020. C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.
cytokines
32490733 2020. Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans.
